Why the study?
Does mitochondrially targeted restriction endonuclease ApaLI shift mtDNA heteroplasmy in heteroplasmic mice?
Population
Heteroplasmic mice and cultured hepatocytes from these mice
Design
Preclinical
Follow-up
2-6 hours (in vitro)
Authors
Loading...
Hypothesis-generating for mtDNA disease therapy; human trials required before clinical consideration.
Does mitochondrially targeted restriction endonuclease ApaLI shift mtDNA heteroplasmy in heteroplasmic mice?
Expression of a mitochondrially targeted restriction endonuclease can rapidly and directionally shift mtDNA heteroplasmy in vivo, offering a potential therapeutic strategy for mitochondrial diseases.
Bayona‐Bafaluy et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: